Department of Neurology Faculty

Robert H. Vonderheide, MD, DPhil

faculty photo
Hanna Wise Professor in Cancer Research
Attending Physician, Hospital of the University of Pennsylvania, Philadelphia, PA
Investigator, Abramson Family Cancer Research Institute
Member, Abramson Cancer Center, University of Pennsylvania School of Medicine
Attending Physician, VA Medical Center, Philadelphia, PA
Program Co-Leader, Immunobiology Program, Abramson Cancer Center, University of Pennsylvania
Associate Director for Translational Research, Abramson Cancer Center, University of Pennsylvania
Vice Chief for Research, Hematology-Oncology Division, Perelman School of Medicine, University of Pennsylvania
Department: Medicine

Contact information
8-121 Smilow Center for Translational Research
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-573-4265
Fax: 215-573-2652
Lab: 215-746-8901 Mark Sudell
Graduate Group Affiliations
BSc (Chemical Engineering)
University of Notre Dame, 1985.
DPhil (Immunology)
Oxford University, 1989.
Harvard Medical School, 1993.
Post-Graduate Training
Intern in Medicine, Massachusetts General Hospital, 1993-1994.
Resident, Internal Medicine, Massachusetts General Hospital, 1994-1996.
Fellow in Hematology/Oncology, Dana-Farber Cancer Institute, 1996-1999.
American Board of Internal Medicine (Internal Medicine), 1996.
American Board of Internal Medicine (Medical Oncology), 2000.
American Board of Internal Medicine (Medical Oncology), Recertification 2010-2020, 2010.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Medical Oncology and Experimental Therapeutics, in particular Immunotherapy

Selected Publications

Markosyan N, Chen EP, Evans RA, Ndong V, Vonderheide RH, Smyth EM: Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity. Breast Cancer Research 15(5): R75 [Epub ahead of print] Sep 3 2013.

Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer P: A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clinical Cancer Research Page: [Epub ahead of print] Sep 4 2013.

Bayne LJ, Vonderheide RH: A myeloid-derived suppressor cell-mediated T-cell suppression assay for functional evaluation of immune cells in tumor-bearing mice. Cold Spring Harb Protoc. 2013(9), Sep 1 2013.

Vonderheide RH,Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O : Phase I study of CD40 antibody CP-870,893 in combination with carboplatin and paclitaxel in patients with advanced solid tumors OncoImmunology 2: e23033, 2013.

Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, Kalos M, Vonderheide RH, Albelda SM, June CH, Zhang PJ. : Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Can Res Treat 133: 799-804, 2012.

Doi H, Iyer TK, Carpenter E, Li H, Chang KM, Vonderheide RH, Kaplan DE: Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-Positive B-cell population. Hepatology 55: 709-719, 2012.

Meisel JL, Domchek SM, Vonderheide RH, Giobbie-Hurder A, Lin NU, Winer EP, Partridge AH: Quality of life in long-term survivors of metastatic breast cancer. Clin Breast Cancer 12: 119-126, 2012.

Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH, Tweed CK, DeMichele A, Fox KR, Domchek SM, Riley JL, Vonderheid RH: CD25 blockade depletes and selectively reprograms regulatory T-cells in concert with immunotherapy in cancer patients Science Translational Medicine 4: 134ra62, 2012.

Rhim AD, Mirek ET, Aiello N, Maitra A, Beatty GL, Bailey JM, Reichert M, Vonderheide RH, Leach SD, Stanger BZ : EMT and dissemination precede pancreatic tumor formation. Cell 148: 349-361, 2012.

Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH : Tumor-derived granulocyte-macrophage colony stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21: 822-835, 2012.

back to top
Last updated: 08/25/2014
The Trustees of the University of Pennsylvania